Wednesday, September 30, 2015 9:04:31 PM
Let's hope so. I have been tempted to reinvest in MNTA, especially at recent prices, but the enoxaparin litigation still vexes me. It's tough for me to accept the possibility that the Federal Circuit could award Amphastar damages for the MNTA patented IP that it stole. I also have no sense of how long the MNTA/Sandoz generic Copaxone will retain its status as the sole generic. However, I do think that MNTA's other programs represent an enticing investment.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM